Articles Tập 67 Số CĐ13-HNKH Bệnh viện 19-8 10/09/2026

UPDATES IN DIAGNOSIS AND MANAGEMENT OF OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: THE ROLE OF PERCUTANEOUS ALCOHOL SEPTAL ABLATION – A CASE REPORT

Hùng Phạm Mạnh, Niên Dương Hồng, Bảng Đỗ Kim, Đạt Bùi Thành, Mạnh Lê, Điệp Hoàng Phi, Nghĩa Phan Đình, Đạt Lê Văn
DOI: 10.52163/yhc.v67iCD13.6392
0 Views
0 Downloads
Keywords
hypertrophic cardiomyopathy, left ventricular outflow tract obstruction, alcohol septal ablation, systolic anterior motion, mitral regurgitation.
Abstract

Objective: To report a case of severe obstructive hypertrophic cardiomyopathy (HOCM) managed with percutaneous alcohol septal ablation (ASA) and to review current diagnostic and therapeutic updates.

Methods: A single case report (CARE guideline) combined with a narrative literature review of current guidelines and trials through July 2026.

Results: A 76-year-old woman with severe HOCM and an invasively measured resting peak-to-peak left ventricular outflow tract gradient of 170 mmHg and severe SAM-related mitral regurgitation underwent ASA (4 mL absolute alcohol into the first septal branch), reducing the gradient to 31 mmHg immediately, with no high-grade atrioventricular block and discharge on day 5.

Conclusion: In an elderly patient at high surgical risk with favorable septal anatomy, ASA is a feasible and hemodynamically effective septal-reduction option at experienced centers, requiring close surveillance for conduction complications and long-term outcomes.

References
[1]
1. Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79(4):372-389. doi:10.1016/j.jacc.2021.12.002 Google Scholar
[2]
2. Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy. Circulation. 2024;149(23):e1239-e1311. doi:10.1161/CIR.0000000000001250 Google Scholar
[3]
3. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-1254. doi:10.1016/j.jacc.2015.01.019 Google Scholar
[4]
4. Sherrid MV, Balaram S, Kim B, Axel L, Swistel DG. The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context. J Am Coll Cardiol. 2016;67(15):1846-1858. doi:10.1016/j.jacc.2016.01.071 Google Scholar
[5]
5. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503-3626. doi:10.1093/eurheartj/ehad194 Google Scholar
[6]
6. Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130(6):484-495. doi:10.1161/CIRCULATIONAHA.113.007094 Google Scholar
[7]
7. Nguyen MT, Hibbert B, Lim S, Le May M, Labinaz M. Alcohol septal ablation for hypertrophic cardiomyopathy: contemporary techniques, outcomes and complications. Cardiol Rev. 2023;31(2):88-96. doi:10.1097/CRD.0000000000000437 Google Scholar
[8]
8. Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769. doi:10.1016/S0140-6736(20)31792-X Google Scholar
[9]
9. Pelliccia F, Cecchi F, Olivotto I, et al. ESC and AHA/ACC guidelines on the management of hypertrophic cardiomyopathy: differences and similarities. Eur Heart J. 2024;45(15):1295-1298. doi:10.1093/eurheartj/ehae033 Google Scholar
[10]
10. Veselka J, Faber L, Jensen MK, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J. 2016;37(19):1517-1523. doi:10.1093/eurheartj/ehv693 Google Scholar
[11]
11. Sedláček K, Schwarz M, Tomek J, et al. Conduction abnormalities after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Europace. 2022;24(6):939-947. doi:10.1093/europace/euab304 Google Scholar
[12]
12. Liebregts M, Vriesendorp PA, Mahmoodi BK, Schinkel AF, Michels M, ten Berg JM. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Heart Fail. 2015;3(11):896-905. doi:10.1016/j.jchf.2015.06.011 Google Scholar
[13]
13. Maron MS, Masri A, Nassif ME, et al. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy (SEQUOIA-HCM). N Engl J Med. 2024;390(20):1849-1861. doi:10.1056/NEJMoa2401045 Google Scholar
[14]
14. Garcia-Pavia P, Maron MS, Masri A, et al. Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy (MAPLE-HCM). N Engl J Med. 2025;393(10):949-960. doi:10.1056/NEJMoa2504654 Google Scholar